Related Experiment Video

Updated: Aug 17, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Gamma-glutamyl transferase and metabolic risk factors for cardiovascular disease

Hidenari Sakuta1, Takashi Suzuki, Hiroko Yasuda

  • 1Department of Internal Medicine, Self-Defense Forces Central Hospital, Tokyo.

Internal Medicine (Tokyo, Japan)
|July 16, 2005
PubMed

Insights

Serum gamma-glutamyl transferase (GGT) activity is linked to cardiovascular risk factors like high cholesterol and blood pressure. This finding suggests GGT may indicate broader health issues beyond just alcohol consumption or obesity.

Area of Science:

  • Cardiovascular Disease Research
  • Biomarker Analysis
  • Metabolic Syndrome

Background:

  • Serum gamma-glutamyl transferase (GGT) activity has been associated with cardiovascular mortality.
  • The underlying mechanisms linking GGT to cardiovascular outcomes require further elucidation.

Purpose of the Study:

  • To investigate the relationship between serum GGT activity and established cardiovascular disease risk factors.
  • To explore the potential role of GGT as a marker for cardiovascular risk.

Main Methods:

  • Cross-sectional analysis was conducted on middle-aged Japanese male personnel.
  • Serum GGT activity was assessed in relation to lipid profiles, glucose levels, homocysteine, and blood pressure.
  • Statistical adjustments were made for confounders such as smoking, alcohol intake, and BMI.

Main Results:

  • Serum GGT activity showed significant associations with total cholesterol, triglycerides, fasting plasma glucose, total homocysteine, and systolic blood pressure.
  • These associations persisted after adjusting for potential confounding factors.
  • The findings suggest GGT is linked to multiple cardiovascular risk factors.

Conclusions:

  • The association between serum GGT and cardiovascular risk factors may partially explain its link to cardiovascular mortality.
  • Serum GGT activity could serve as a valuable marker for cardiovascular risk factors or oxidative stress.
  • GGT may be more than just an indicator of excessive alcohol consumption or obesity.
Abstract

More Related Videos

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...